Keith Beaulieu, MD
Pulmonary Disease · Lancaster, PANPI 1043474364
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,000 of the $4,055 with a category attached, or 74.0%. Intuitive Surgical accounts for 90.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $3,593 and has fallen 93.6% since, to $228 in 2025.
Across 16 payments — averaging $253.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$149
- Abiomed$126
- Regeneron Healthcare Solutions, Inc.$35
- Insmed, Inc.$32
- Novartis$17
- plus $11 from 1 others
What the payments were for
- Travel & lodging$49912%
- Food & beverage$55614%
- Education$3,00074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $3,685 |
| AstraZeneca(2 entities) | 2 | $149 |
| Abiomed | 1 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Insmed, Inc. | 1 | $32 |
| Novartis | 1 | $17 |
| Breas Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,499
- ULTOMIRIS$125
How this compares
$4,055 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 19 | $110,009 |
| EliquisApixaban | 59 | $35,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $26,282 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $17,956 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,702 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,369 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $4,426 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,685 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,651 |
| Roflumilast | 18 | $969 |
| Ventolin HfaAlbuterol Sulfate | 13 | $701 |
| Prednisone | 105 | $477 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lancaster
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.